Prostate Cancer [Radium-223 chloride (Xofigo) (Wave 2)] | LaunchTrends | US | 2014

LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer HealthCare’s radium-223).
LaunchTrends®: Xofigo measures the impact of this new agent on the metastatic castrate-resistant prostate cancer (mCRPC) market following launch, based on a blend of quantitative and qualitative primary research with U.S. medical oncologists. These reports evaluate physicians’ current awareness and perception of Xofigo relative to other currently available therapies for mCRPC, current and anticipated use of Xofigo, and promotional activity of Xofigo.

Login to access report

launch Related Market Assessment Reports